Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer and Metastasis Reviews
Published in: Cancer and Metastasis Reviews 3-4/2011

01-12-2011

Cyclooxygenase-dependent signaling is causally linked to non-melanoma skin carcinogenesis: pharmacological, genetic, and clinical evidence

Author: Karin Müller-Decker

Published in: Cancer and Metastasis Reviews | Issue 3-4/2011

Login to get access

Abstract

Cyclooxygenase (COX)-derived prostaglandins (PGs) exhibit manifold functions in acute and chronic skin inflammation induced by a number of physical (ultraviolet (UV) light, wounding) and chemical (12-O-tetradecanoylphorbol 13-acetate (TPA), arachidonic acid) noxious stimuli. Depending on the challenge and the context, constitutively expressed COX-1 or the transiently induced COX-2 isoform are of relevance. Moreover, squamous cell carcinoma (SCC) of skin is a prominent example of epithelial neoplasia that consistently overexpresses COX-2 in the parenchyme and the mesenchyme of premalignant and malignant lesions, while COX-1 expression remains unaltered. Pharmacological, clinical, and experimental animal studies as well as a few epidemiological studies document the importance of PG signaling in non-melanoma skin cancer including SCC and basal cell carcinoma (BCC) in humans and mice. Increased levels of PGE2 and PGF2α in premalignant and/or malignant epithelial skin cancers are due to the constitutive upregulation of enzymes involved in PG biosynthesis, such as COX-2, and downregulation of the tumor suppressor gene 15-hydroxy-prostaglandin dehydrogenase (15-PGDH), which is involved in the inactivation of PG, thus counteracting the activities of COX. Most remarkably, genetic studies show that mice which are deficient in COX-2 or COX-1 are protected from the development of SCC when applying the multi-stage chemical carcinogenesis protocol. Conversely, the forced overexpression of COX-2 in the proliferative basal compartment of the stratified skin epidermis results in spontaneous hyperplasia and dysplasia in transgenic mice and furthermore a sensitization for cancer development by conferring an auto-promoted skin phenotype. In multi-stage carcinogenesis, it also becomes clear that aberrant COX-2 overexpression and activity are causally involved in tumor promotion and tumor progression rather than initiation. In contrast, using as inducer of carcinogenesis the complete carcinogen UV B light, depletion of COX-2 but not of COX-1 makes mouse skin resistant for SCC, indicating that here, only COX-2 is essential. Depending on the type of challenge, COX-2-dependent signaling contributes to the pre-invasive growth of the skin epidermis by a delayed onset of terminal differentiation, or stimulation of hyperproliferation and survival. With respect to BCC, the genetic ablation of COX-2 but also of COX-1 leads to a strongly reduced tumor burden in the skin of Patched (Ptch)1+/− mice, which due to the deletion of a Ptch1 allele, spontaneously develop BCC resembling human familial basal cell nevus syndrome and sporadic BCC. Nonsteroidal anti-inflammatory drugs and the COX-2-selective inhibitors (COXibs) exhibit impressive efficacy inhibiting tumor burden in various mouse models of SCC and BCC. Most importantly, in humans the interruption of COX-2 signaling is an effective strategy to treat and chemo-prevent non-melanoma skin cancer in individuals who are at high risk for the disease. However, any potential beneficial effect of this medicine has to be balanced against the adverse effects that are known to be associated with these drugs in a subset of patients.
Literature
1.
Szabowsky, A., Maas-Szabowski, N., Andrecht, S., Kolbus, A., Schorpp-Kistner, M., Fusenig, N. E., et al. (2000). C-Jun and JunB antagonistically control cytokine-regulated mesenchymal-epidermal interaction in skin. Cell, 103, 745–755.
2.
Boulais, N., & Misery, L. (2008). The epidermis: a sensory tissue. European Journal of Dermatology, 18, 119–127.PubMed
3.
Fuchs, E., & Raghavan, S. (2002). Getting under the skin of epidermis. Nature Reviews of Genetics, 3, 199–209.
4.
Candi, E., Schmidt, R., & Melino, G. (2005). The cornified envelope: a model of cell death in the skin. Nature, 6, 328–340.
5.
Koster, M. I., & Roop, D. R. (2007). Mechanisms regulating epithelial stratification. Annual Review of Cell and Developmental Biology, 23, 93–113.PubMed
6.
Feingold, K. R. (2007). The role of epidermal lipids in cutaneous permeability barrier homeostasis. Journal of Lipid Research, 48, 2531–2546.PubMed
7.
Delfino-Machin, M., Chipperfield, T. R., Rodrigues, S. L. M., & Kelsh, R. N. (2007). The proliferating field of neural crest stem cells. Developmental Dynamics, 236, 3242–3254.PubMed
8.
Romani, N., Clausen, B. E., & Stoitzner, P. (2010). Langerhans cells and more: Langerin-expressing dendritic cell subsets in the skin. Immunology Reviews, 234, 120–141.
9.
Lin, J. Y., & Fisher, D. E. (2007). Melanocyte biology and skin pigmentation. Nature, 445, 843–850.PubMed
10.
Gray-Schopfer, V., Wellbrock, C., & Marais, R. (2007). Melanoma biology and new targeted therapy. Nature, 445, 851–857.PubMed
11.
Merad, M., Ginhoux, F., & Collin, M. (2008). Origin, homeostasis and function of Langerhans cells and other langerin-expressing dendritic cells. Nature Reviews of Immunology, 8, 935–947.
12.
Maricich, S. M., Wellnitz, S. A., Nelson, A. M., Lesniak, D. R., Gerling, G. J., Lumpkin, E. A., et al. (2009). Merkel cells are essential for light-touch responses. Science, 324, 1580–1582.PubMed
13.
Van Keymeulen, A., Mascre, G., Youseff, K. K., Harel, I., Michaux, C., De Geest, N., et al. (2009). Epidermal progenitors give rise to Merkel cells during embryonic development and adult homeostasis. The Journal of Cell Biology, 187, 91–100.PubMed
14.
Lewis, J. M., Girardi, M., Roberts, S. J., Barbee, S. D., Hayday, A. C., & Tigelaar, R. E. (2006). Selection of the cutaneous intraepithelial γδ+ T cell repertoire by a thymic stromal determinant. Nature Immunology, 7, 843–850.PubMed
15.
Sumaria, N., Roedinger, B., Ng, L. G., Qin, J., Pinto, R., Cavanagh, L. L., et al. (2011). Cutaneous immunosurveillance by self-renewing dermal gammadelta T cells. The Journal of Experimental Medicine, 208, 505–518.PubMed
16.
Bonventre, J. V., Huang, Z., Taheri, M. R., O’Leahy, E., Li, E., Moskowitz, M. A., et al. (1997). Reduced fertility and postischaemic brain injury in mice deficient in cytosolic phospholipase A2. Nature, 390, 622–625.PubMed
17.
Hirabashi, T., Murayama, T., & Shimizu, T. (2004). Regulatory mechanism and physiological role of cytosolic phospholipase A2. Biological and Pharmacological Bulletin, 27, 1168–1173.
18.
Smith, W. L., Dewitt, D. L., & Garavito, R. M. (2000). Cyclooxygenases: structural, cellular, andmolecular biology. Annual Reviews of Biochemistry, 69, 145–182.
19.
Hara, S., Kamei, D., Sasaki, Y., Tanemoto, A., Nakatani, Y., & Murakami, M. (2010). Prostaglandin E synthases: understanding their pathophysiological roles through mouse genetic models. Biochemie, 92, 651–659.
20.
Helliwell, R. J., Adams, L. F., & Mitchell, M. D. (2004). Prostaglandin synthases: recent developments and a novel hypothesis. Prostaglandins, Leukotrienes, and Essential Fatty Acids, 70, 101–113.PubMed
21.
Reid, G., Wielinga, P., Zelcer, N., van der Heijden, I., Kuil, A., de Haas, M., et al. (2003). The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal anti-inflammatory drugs. Proceedings of the National Academy of Sciences of the United States of America, 100, 9244–9249.PubMed
22.
Woodward, D.F., Jones, R.L., & Narumiya, S. (2011). International union of basic and clinical pharmacology, classification of prostanoid receptors, updating 15 years of progress. Pharmacological Reviews, 63, 471–538.
23.
Hata, N. A., & Breyer, R. M. (2004). Pharmacology and signalling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacology and Therapeutics, 103, 147–166.PubMed
24.
Wang, D., & DuBois, R. N. (2007). Inflammatory mediators and nuclear receptor signaling in colorectal cancer. Cell Cycle, 6, 682–685.PubMed
25.
Schuster, V. L. (2002). Prostaglandin transport. Prostaglandins and Lipid Mediators, 68–69, 633–647.
26.
Myung, S. J., Rerko, R. M., Yan, M., Platzer, P., Guda, K., Dotson, A., et al. (2006). 15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America, 103, 12098–12102.PubMed
27.
Wolf, I., O’Kelly, J., Rubinek, T., Tong, M., Nguyen, A., Lin, B. T., et al. (2006). 15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer. Cancer Research, 66, 7818–7823.PubMed
28.
Ding, Y., Tong, M., Liu, S., Moscow, J. A., & Tai, H. H. (2005). NAD + −linked 15-hydroxyprostaglandin dehydrogenase (15-PGDH) behaves as a tumor suppressor in lung cancer. Carcinogenesis, 26, 65–72.PubMed
29.
Mann, J. R., Backlund, M. G., Buchanan, F. G., Daikoku, T., Holla, V. R., Rosenberg, D. W., et al. (2006). Repression of prostaglandin dehydrogenase by epidermal growth factor and snail increases prostaglandin E2 and promotes cancer progression. Cancer Research, 66, 6649–6656.PubMed
30.
Judson, B. L., Miyaki, A., Kekapture, V. D., Du, B., Gilleaudeau, P., Sullivan-Whalen, M., et al. (2010). UV radiation inhibits 15-hydroxyprostaglandin dehydrogenase levels in human skin: evidence of transcriptional suppression. Cancer and Prevention Research, 3, 1104–1111.
31.
Simmons, D. L., Botting, R. M., & Hla, T. (2004). Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacological Reviews, 56, 387–437.PubMed
32.
Loftin, C. D., Tiano, H. F., & Langenbach, R. (2002). Phenotypes of the COX-deficient mice indicate physiological and pathophysiological roles for COX-1 and COX-2. Prostaglandins and Lipid Mediators, 68–69, 177–185.
33.
Cha, Y. I., & DuBois, R. N. (2007). NSAIDs and cancer prevention: targets downstream of COX-2. Annual Reviews of Medicine, 58, 239–252.
34.
Blackwell, K. A., Raisz, L. G., & Pilbeam, C. C. (2010). Prostaglandins in bone: bad cop, good cop? Trends in Endocrinoogy and Metabolism, 21, 294–300.
35.
Vegiopoulos, A., Müller-Decker, K., Strzoda, D., Schmitt, I., Chichelnitskiy, E., Ostertag, A., et al. (2010). Cyclooxygenase-2 controls energy homeostasis in mice by de novo recruitment of brown adipocytes. Science, 328, 1158–1161.PubMed
36.
Wang, D., & DuBois, R. N. (2010). The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene, 29, 781–788.PubMed
37.
Wang, D., & DuBois, R. N. (2010). Eicosanoids and cancer. Nature Reviews. Cancer, 10, 181–194.PubMed
38.
Wong, D., Wang, M., Cheng, Y., & FitzGerald, G. A. (2005). Cardiovascular hazard and non-steroidal anti-inflammatory drugs. Current Opinion in Pharmacology, 5, 204–210.PubMed
39.
Marks, F., Fürstenberger, G., Neufang, G., & Müller-Decker, K. (2003). Mouse skin as a model for cancer chemoprevention by nonsteroidal anti-inflammatory drugs. Recent Results in Cancer Research, 163, 46–57.PubMed
40.
Tegeder, I., Pfeilschifter, J., & Geisslinger, G. (2001). Cyclooxygenase-independent actions ofcyclooxygenase inhibitors. The FASEB Journal, 15, 2057–2072.PubMed
41.
Raz, A. (2002). Is inhibition of cyclooxygenase required for the anti-tumorigenic effects ofnon-steroidal, anti-inflammatory drugs (NSAIDs)? In vitro versus in vivo results and the relevance for the prevention and treatment of cancer. Biochemical Pharmacology, 63, 343–347.PubMed
42.
Goldyne, M. E. (2000). Cyclooxygenase isoforms in human skin. Prostaglandins and Other Lipid Mediators, 63, 15–23.PubMed
43.
Gledhill, K., Rhodes, L. E., Brownrigg, M., Haylett, A. K., Masoodi, M., Thody, A. J., et al. (2010). Prostaglandin-E2 is produced by adult human epidermal melanocytes in response to UVB in a melanogenesis-independent manner. Pigment and Melanoma Research, 23, 394–403.
44.
Maciejewski-Lenoir, D., Richman, J. G., Habak, Y., Gaidarov, I., Behan, D. P., & Connolly, D. T. (2006). Langerhans cells release prostaglandin D2 in response to nicotinic acid. Journal of Investigative Dermatology, 126, 2637–2646.PubMed
45.
Shimura, C., Satoh, T., Igawa, K., Aritake, K., Urade, Y., Nakamura, M., et al. (2010). Dendritic cells express hematopoietic prostaglandin D synthase and function as a source of prostaglandin D2 in the skin. American Journal of Pathology, 176, 227–237.PubMed
46.
Ziboh, V. A. (1996). The significance of polyunsaturated fatty acids in cutaneous biology. Lipids, 31, 249–253.
47.
Müller-Decker, K., Leder, C., Neumann, M., Neufang, G., Bayerl, C., Schweizer, J., et al. (2003). Expression of cyclooxygenase isozymes during morphogenesis and cycling of pelage hair follicles in mouse skin: precocious onset of the first catagen phase and alopecia upon cyclooxygenase-2 overexpression. Journal of Investigative Dermatology, 121, 661–668.PubMed
48.
Müller-Decker, K., Scholz, K., Neufang, G., Marks, F., & Fürstenberger, G. (1998). Localization of prostaglandin-h synthase-1 and −2 in mouse skin: Implications for cutaneous function. Experimental Cell Research, 242, 84–91.PubMed
49.
Müller-Decker, K., Reinerth, G., Krieg, P., Zimmermann, R., Heise, H., Bayerl, C., et al. (1999). Prostaglandin-h-synthase isozyme expression in normal and neoplastic human skin. International Journal of Cancer, 82, 648–656.
50.
Alestas, T., Ganceviciene, R., Fimmel, S., Müller-Decker, K., & Zouboulis, C. C. (2006). Enzymes involved in the biosynthesis of leukotriene B4 and prostaglandin E2 are active in sebaceous glands. Journal of Molecular Medicine, 84, 75–87.PubMed
51.
Abd-El-Aleem, S. A., Ferguson, M. W. J., Appleton, I., Bhowmick, A., McCollum, C. N., & Ireland, G. W. (2001). Expression of cyclooxygenase isoforms in normal human skin and chronic venous ulcers. The Journal of Pathology, 195, 616–623.PubMed
52.
Kagoura, M., Toyoda, M., Matsui, C., & Morohashi, M. (2001). Immunohistochemical expression of cyclooxygenase-2 in skin cancers. Journal of Cutaneous Pathology, 28, 298–302.PubMed
53.
Akunda, J. K., Lao, H. C., Lee, C. A., Sessoms, A. R., Slade, R. M., & Langenbach, R. (2004). Genetic deficiency or pharmacological inhibition of cyclooxygenase-1 or −2 induces mouse keratinocyte differentiation in vitro and in vivo. The FASEB Journal, 18, 185–187.PubMed
54.
Leong, J., Hughes-Fulford, M., Rakhlin, N., Habib, A., Maclouf, J., & Goldyne, M. E. (1996). Cyclooxygenase in human and mouse skin and cultured human keratinocytes: association of COX-2 expression with human keratinocyte differentiation. Experimental Cell Research, 224, 79–87.PubMed
55.
Hruza, L. L., & Pentland, A. P. (1993). Mechanisms of UV-induced inflammation. Journal of Investigative Dermatology, 100, 35S–41S.PubMed
56.
Williams, I. R., & Kupper, T. S. (1996). Immunity at the surface: homeostatic mechanisms of the skin immune system. Life Sciences, 58, 1485–1507.PubMed
57.
Ruzicka, T., Walter, J. F., & Printz, M. P. (1983). Changes in arachidonic acid metabolism in UV-irradiated hairless mouse skin. Journal of Investigative Dermatology, 81, 300–303.PubMed
58.
Pentland, A. P., & Jacobs, S. C. (1991). Bradykinin-induced prostaglandin synthesis is enhanced in keratinocytes and fibroblasts by UV injury. American Journal of Physiology, 261, R543–R547.PubMed
59.
Kuwamoto, K., Miyauchi-Hashimoto, H., Tanaka, K., Eguchi, N., Inui, T., Urade, Y., et al. (2000). Possible involvement of enhanced prostaglandin E2 production in the photosensitivity in xeroderma pigmentosum group A model mice. Journal of Investigative Dermatology, 114, 241–246.PubMed
60.
Goldyne, M. E., & Evans, C. B. (1994). 12-O-Tetradecanoylphorbol-13-acetate and the induction ofprostaglandin E2 generation by human keratinocytes: A re-evaluation. Carcinogenesis, 15, 141–143.PubMed
61.
Müller-Decker, K., Scholz, K., Marks, F., & Fürstenberger, G. (1995). Differential expression of prostaglandin h synthase isozymes during multistage carcinogenesis in mouse epidermis. Molecular Carcinogenesis, 12, 31–41.PubMed
62.
Black, A. K., Greaves, M. W., Hensby, C. N., & Pummer, N. A. (1978). Increased prostaglandins E2 and F2α in human skin at 6 and 24 h after ultraviolet B irradiation (290–320 nm). British Journal of Clinical Pharmacology, 5, 431–436.PubMed
63.
Williams, T. J. (1979). Prostaglandin E2, prostaglandin I2, and the vascular changes of inflammation. British Journal of Pharmacology, 65, 517–524.PubMed
64.
Williams, T. J., & Peck, M. J. (1977). Role of prostaglandin-mediated vasodilatation in inflammation. Nature, 270, 530–532.PubMed
65.
Pentland, A. P., Mahoney, M., Jacobs, S., & Holtzmann, M. J. (1990). Enhanced prostaglandin synthesis after ultraviolet injury is mediated by endogenous histamine stimulation. Journal of Clinical Investigation, 86, 566–574.PubMed
66.
Rhodes, L. E., Belgi, G., Parslew, R., McLoughlin, L., Clough, G. F., & Friedman, P. S. (2001). Ultraviolet-B-induced erythema is mediated by nitric oxide and prostaglandin E2 in combination. Journal of Investigative Dermatology, 117, 880–885.PubMed
67.
Davis, P., Bailey, P. J., Goldenberg, M. M., & Ford-Hutchinson, A. W. (1984). The role of arachidonic acid oxygenation products in pain and inflammation. Annual Reviews of Immunology, 2, 335–357.
68.
Murata, T., Ushikubi, F., Matsuoka, T., Hirata, M., Yamasaki, A., Sugimoto, Y., et al. (1997). Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature, 388, 678–682.PubMed
69.
Ferreira, S. H. (1981). Inflammatory pain, prostaglandin hyperalgesia and the development of peripheral analgesia. Trends in Pharmacological Sciences, 12, 183–186.
70.
Balsinde, J., Balboa, M. A., Insel, P. A., & Dennis, E. A. (1999). Regulation and inhibition of phopholipase A2. Annual Reviews of Pharmacology and Toxicology, 39, 175–189.
71.
Kast, R., Fürstenberger, G., & Marks, F. (1993). Phorbol-ester TPA- and bradykinin-induced arachidonic acid release from keratinocytes is catalyzed by a cytosolic phospholipase A2 (cPLA2). Journal of Investigative Dermatology, 101, 567–572.PubMed
72.
Gresham, A., Masferrer, J., Chen, X., Leal-Khouri, S., & Pentland, A. P. (1996). Increased synthesis of high- molecular-weight cPLA2 mediates early UV-induced PGE2 in human skin. American Journal ofPhysiology, 270, C1037–C1050.
73.
Kang-Rotondo, C. H., Miller, C. C., Morrison, A. R., & Pentland, A. P. (1993). Enhanced keratinocyte prostaglandin synthesis after UV injury is due to increased phospholipase activity. American Journal of Physiology, 264, C396–C401.PubMed
74.
Scholz, K., Fürstenberger, G., Müller-Decker, K., & Marks, F. (1995). Differential expression of prostaglandin H-synthase isoenzymes in normal and activated keratinocytes in vivo and in vitro. Biochemical Journal, 306, 263–269.
75.
Fürstenberger, G., & Marks, F. (1980). Early prostaglandin E synthesis is an obligatory event in the induction of cell proliferation in mouse epidermis in vivo by the phorbolester TPA. Biochemical and Biophysical Research Communication, 92, 749–756.
76.
Buckman, S. Y., Gresham, A., Hale, P., Hruza, G., Anast, J., Masferrer, J., et al. (1998). COX-2 expression is induced by UVB exposure in human skin: Implications for the development of skin cancer. Carcinogenesis, 19, 723–729.PubMed
77.
Soriani, M., Luscher, P., & Tyrrell, R. M. (1999). Direct and indirect modulation of ornithine decarboxylase and cyclooxygenase by UVB radiation in human skin cells. Carcinogenesis, 20, 727–732.PubMed
78.
Athar, M., An, K. P., Morel, K. D., Kim, A. L., Aszterbaum, M., Longley, J., et al. (2001). Ultraviolet B (UVB)-induced COX-2 expression in murine skin: an immunohisto-chemical study. Biochemical and Biophysical Research Communication, 280, 1042–1047.
79.
An, K. P., Athar, M., Tang, X., Katiyar, S. K., Russo, J., Beech, J., et al. (2002). Cyclooxygenase-2 expression in murine and human nonmelanoma skin cancers: implications for therapeutic approaches. Photochemistry and Photobiology, 76, 73–80.PubMed
80.
Tripp, C. S., Blomme, E. A. G., Chinn, K. S., Hardy, M. M., LaCelle, P., & Pentland, A. P. (2003). Epidermal COX-2 induction following ultraviolet irradiation: suggested mechanism for the role of COX-2 inhibition in photoprotection. Journal of Investigative Dermatology, 121, 1–9.
81.
Dazard, J. E., Gal, H., Amariglio, N., Rechavi, G., Domany, E., & Givol, D. (2003). Genome-wide comparison of human keratinocyte and squamous carcinoma responses to UVB irradiation: implication for skin and epithelial cancer. Oncogene, 22, 2993–3006.PubMed
82.
Akunda, J. K., Chun, K. S., Sessoms, A. R., Lao, H. C., Fischer, S. M., & Langenbach, R. (2007). Cyclooxygenase-2 deficiency increases epidermal apoptosis and impairs recovery following acute UVB exposure. Molecular Carcinogenesis, 46, 354–362.PubMed
83.
Morham, S. G., Langenbach, R., Loftin, C. D., Tiano, H. F., Vouloumanos, N., Jennette, J. C., et al. (1995). Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell, 83, 473–482.PubMed
84.
Langenbach, R., Morham, S. G., Tiano, H. F., Loftin, C. D., Ghanayem, B. I., Chulada, P. C., et al. (1995). Prostaglandin synthase 1 gene disruption in mice reduced arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell, 83, 483–492.PubMed
85.
Neufang, G., Fürstenberger, G., Heidt, M., Marks, F., & Müller-Decker, K. (2001). Abnormal differentiation of epidermis in transgenic mice constitutively expressing cyclooxygenase-2 in skin. Proceedings of the National Academy of Sciences of the United States of America, 98, 7629–7634.PubMed
86.
Neumann, M., Dülsner, E., Fürstenberger, G., & Müller-Decker, K. (2007). The expression pattern of prostaglandin E synthase and EP receptor isoforms in normal mouse skin and preinvasive neoplasms. Experimental Dermatology, 16, 445–453.PubMed
87.
Tiano, H. F., Loftin, C. D., Akunda, J., Lee, C. A., Spalding, J., Sessoms, A., et al. (2002). Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis. Cancer Research, 62, 3395–3401.PubMed
88.
Pentland, A. P., Scott, G., VanBuskirk, J., Tranck, C., LaRossa, G., & Brouxhon, S. (2004). Cyclooxygenase-1 deletion enhances apoptosis but does not protect against ultraviolet light-induced tumors. Cancer Research, 64, 5587–5591.PubMed
89.
Hoshino, T., Tsutsumi, S., Tomisato, W., Hwang, H. J., Tsuchiya, T., & Mizushima, T. (2003). Prostaglandin E2 protects gastric mucosal cells from apoptosis via EP2 and EP4 receptor activation. Journal of Biological Chemistry, 278, 12752–12758.PubMed
90.
Houchen, C. W., Sturmoski, M. A., Anant, S., Breyer, R. M., & Stenson, W. F. (2003). Prosurvival and antiapoptotic effects of PGE2 in radiation injury are mediated by EP2 receptor in intestine. American Journal of Gastrointestinal and Liver Physiology, 284, G490–G498.
91.
Chun, K. S., Akunda, J. K., & Langenbach, R. (2007). Cyclooxygenase-2 inhibits UVB-induced apoptosis in mouse skin by activating the PGE2 receptors EP2 and EP4. Cancer Research, 67, 2015–2020.PubMed
92.
Chun, K. S., & Langenbach, R. (2007). A proposed COX-2 and PGE2 receptor interaction in UV-exposed mouse skin. Molecular Carcinogenesis, 46, 699–704.PubMed
93.
Fischer, S. M., Pavone, A. P., Mikulec, C., Langenbach, R., & Rundhaug, J. E. (2007). Cyclooxygenase-2 expression is critical for UV-induced murine skin carcinogenesis. Molecular Carcinogenesis, 46, 363–371.PubMed
94.
Wilgus, T. A., Ross, M., Parrett, M., & Oberyszyn, T. (2000). Topical application of a selective cyclooxygenase-2 inhibitor suppresses UVB mediated cutaneous inflammation. Prostaglandins & Other Lipid Mediators, 62, 367–384.
95.
Wilgus, T. A., Parrett, M. L., Ross, M. S., Tober, K. L., Robertson, F. M., & Oberyszyn, T. M. (2002). Inhibition of ultraviolet light B-induced cutaneous inflammation by a specific cyclooxygenase-2 inhibitor. Advances in Experimental Medicine and Biology, 507, 85–92.PubMed
96.
Wilgus, T. A., Koki, A. T., Zweifel, B. S., Kusewitt, D. F., Rubal, P. A., & Oberyszyn, T. M. (2003). Inhibition of cutaneous ultraviolet light-B-mediated inflammation and tumor formation with topical celecoxib treatment. Molecular Carcinogenesis, 38, 49–58.PubMed
97.
Black, A. K., Greaves, M. W., & Hensby, C. N. (1980). The anti-inflammatory and pharmacological effects of topically applied flurbiprofen on human skin 24 hours after ultraviolet B irradiation. Prostaglandins and Medicine, 5, 405–413.PubMed
98.
Snyder, D. S., & Eaglestein, W. H. (1974). Intradermal anti-prostaglandin agents and sunburn. Journal of Investigative Dermatology, 62, 47–50.
99.
Rodriguez-Burford, C., Tu, J. H., Mercurio, M. G., Carey, D., Han, R., Gordon, G., et al. (2005). Selective cyclooxygenase-2 inhibition produces heterogenous erythema response to ultraviolet irradiation. Journal of Investigative Dermatology, 125, 1317–1319.PubMed
100.
Moore, D. E. (2002). Drug-induced photosensitivity: incidence, mechanism, prevention and management. Drug Safety, 25, 345–372.PubMed
101.
Fürstenberger, G., Marks, F., & Müller-Decker, K. (2003). Cyclooxygenase-2 and skin carcinogenesis. In Dannenberg AJ, DuBois RN (eds): COX-2, Progress in Experimental Tumor Research, Basel, Karger 37, 72–89.
102.
Lukiw, W. J., Pelaez, R. P., Martinez, J., & Bazan, N. G. (1998). Budesonide epimer R or dexa-methasone selectively inhibit platelet-activating factors and cyclooxygenase-2 gene ex-pression in human epidermal keratinocytes. Proceedings of the National Academy of Sciences of the United States of America, 95, 3914–3919.PubMed
103.
Matsuura, H., Sakaue, M., Subbaramaiah, K., Kamitani, H., Eling, T. E., Dannenberg, A. J., et al. (1999). Regulation of cyclooxygenase-2 by interferon γ and transforming growth factor α in normal human epidermal keratinocytes and squamous carcinoma cells. Journal of Biological Chemistry, 274, 29138–29148.PubMed
104.
Fairly, J. A., Weiss, J., & Marcelo, C. L. (1986). Increased prostaglandin synthesis by low calcium-regulated keratinocytes. Journal of Investigative Dermatology, 86, 173–176.
105.
Kanekura, T., Laulederkind, S. J., Kirtikara, K., Goorha, S., & Ballou, L. R. (1998). Cholecalciferol induces prostaglandin E2 biosynthesis and transglutaminase activity in human keratinocytes. Journal of Investigative Dermatology, 111, 634–639.PubMed
106.
Scott, G., Leopardi, S., Printup, S., Malhi, N., Seiberg, M., & Lapoint, R. (2004). Proteinase-activated receptor-2 stimulates prostaglandin production in keratinocytes: analysis of prostaglandin receptors on human melanocytes and effects of PGE2 and PGF2alpha on melanocyte dendricity. Journal of Investigative Dermatology, 122, 1214–1224.PubMed
107.
Masoodi, M., Nicolaou, A., Gledhill, K., Rhodes, L. E., Tobin, D. J., & Thody, A. J. (2010). Prostaglandin D production in FM melanoma cells is regulated by alpha-melanocyte-stimulating hormone and is not related to melanin production. Experimental Dermatology, 19, 751–753.PubMed
108.
Wang, H. S., Cao, H. J., Winn, V. D., Rezanka, L. J., Frobert, Y., Evans, C. H., et al. (1996). Leukoregulin induction of prostaglandin-endoperoxide H synthase-2 in human orbital fibroblasts. An in vitro model for connective tissue inflammation. Journal of Biological Chemistry, 271, 22718–22728.PubMed
109.
Müller-Decker, K. (1999). Cyclooxygenases. In F. Marks & G. Fürstenberger (Eds.), Postaglandins, leukotrienes and other eicosanoids (pp. 65–88). Weinheim, Germany: Wiley-VCH.
110.
Hla, T., & Neilson, K. (1992). Human cyclooxygenase-2 cDNA. Proceedings of the National Academy of Sciences of the United States of America, 89, 7384–7388.PubMed
111.
Schäfer, M., & Werner, S. (2008). Cancer as an overhealing wound: an old hypothesis revisited. Nature Reviews of Molecular and Cellular Biology, 9, 629–638.
112.
Futagami, A., Ishizaki, M., Fukuda, Y., Kawana, S., & Yamanaka, N. (2002). Wound healing involves induction of cyclooxygenase-2 expression in rat skin. Laboratory Investigation, 82, 1503–1513.PubMed
113.
Müller-Decker, K., Hirschner, W., Marks, F., & Fürstenberger, G. (2002). The effects of cyclooxygenase isozyme inhibition on incisional wound healing in mouse skin. Journal of Invstigative Dermatology, 119, 1189–1195.
114.
Blomme, E. A., Chinn, K. S., Hardy, M. M., Casler, J. J., Kim, S. H., Opsahl, A. C., et al. (2003). Selective cyclooxygenase-2 inhibition does not affect the healing of cutaneous full-thickness incisional wounds in SKH-1 mice. Britisch Journal of Dermatology, 148, 211–223.
115.
Kämpfer, H., Bräutigam, L., Geisslinger, G., Pfeilschifter, J., & Frank, S. (2003). Cyclooxygenase-1-coupled prostaglandin biosynthesis constitutes an essential prerequisite for skin repair. Journal of Investigative Dermatology, 120, 880–890.PubMed
116.
Wilgus, T. A., Vodovotz, Y., Vittadini, E., Clubbs, E. A., & Oberyszyn, T. M. (2003). Reduction of scar formation in full-thickness wounds with topical celecoxib treatment. Wound Repair and Regeneration, 11, 25–34.PubMed
117.
Laulederkind, S. J., Thompson-Jaeger, S., Goorha, S., Chen, Q., Fu, A., Rho, J. Y., et al. (2002). Both constitutive and inducible prostaglandin H synthase affect dermal wound healing in mice. Laboratory Investigation, 82, 919–927.PubMed
118.
Gasparini, G., Longo, R., Sarmiento, R., & Morabito, A. (2003). Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents? The Lancet Oncology, 4, 605–615.PubMed
119.
Dannenberg, A. J., Altorki, N. K., Boyle, J. O., Dang, C., Howe, L. R., Weksler, B. B., et al. (2001). Cyclooxygenase-2: a pharmacological target for the prevention of cancer. The Lancet Oncology, 2, 544–551.PubMed
120.
Lemos, B., & Nghiem, P. (2007). Merkel cell carcinoma: more deaths but still no pathway to blame. Journal of Investigative Dermatology, 127, 2100–2102.PubMed
121.
Koljonen, V., Lassus, P., Tukiainen, E., Ristimäki, A., Haglund, C., & Böhling, T. (2005). Cyclooxygenase-2 expression in primary Merkel cell carcinoma. Journal of Cutaneous Pathology, 32, 55–58.PubMed
122.
Joachims, Z., Feinmesser, R., Purim, O., Halpern, M., Brenner, B., Fenig, E., et al. (2008). Cyclooxygenase-2 expression in primary and metastatic Merkel cell carcinoma. Applied Immunohistochemistry & Molecular Morphology, 16, 442–446.
123.
Gilchrest, B. A., Eller, M. S., Geller, A. C., & Yaar, M. (1999). The pathogenesis of melanoma induced by ultraviolet irradiation. The New England Journal of Medicine, 340, 1341–1348.PubMed
124.
Armstrong, B. K., & Kricker, A. (2001). The epidemiology of UV induced skin cancer. Journal of Photochemistry and Photobiology B: Biology, 63, 8–18.
125.
Ibrahim, N., & Haluska, F. G. (2009). Molecular pathogenesis of cutaneous melanocytic neoplasms. Annual Review of Pathology: Mechanisms of Disease, 4, 551–579.
126.
Denkert, C., Köbel, M., Berger, S., Siegert, A., Leclere, A., Trefzer, U., et al. (2001). Expression of cyclooxygenase 2 in human malignant melanoma. Cancer Research, 61, 303–308.PubMed
127.
Vogt, T., McClelland, M., Jung, B., Popova, S., Bogenrieder, T., Becker, B., et al. (2001). Progression and NSAID-induced apoptosis in malignant melanomas are independent of cyclooxygenase II. Melanoma Research, 11, 587–599.PubMed
128.
Goulet, A. C., Einspahr, J. G., Alberts, D. S., Beas, A., Burk, C., Bhattacharyya, A., et al. (2003). Analysis of cyclooxygenase-2 (COX-2) expression during malignant melanoma progression. Cancer Biology & Therapy, 2, 713–718.
129.
Kuzbicki, L., Sarnecka, A., & Chwirot, B. W. (2006). Expression of cyclooxygenase-2 in benign naevi and during human cutaneous melanoma progression. Melanoma Research, 16, 29–36.PubMed
130.
Chwirot, B. W., & Kuzbicki, L. (2007). Cyclooxygenase 2 (COX-2): first immunohistochemical marker distinguishing early cutaneous melanomas from benign melanocytic skin tumors. Melanoma Research, 17, 139–145.PubMed
131.
Lee, C., Ramirez, J. A., Guitart, J., & Diaz, L. K. (2008). Expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor gamma during malignant melanoma progression. Journal of Cutaneous Pathology, 35, 989–994.PubMed
132.
Diepgen, T. L., & Mahler, V. (2002). The epidemiology of skin cancer. British Journal of Dermatology, 146(Suppl. 61), 1–6.PubMed
133.
DiGiovanna, J. J. (1998). Post transplantation skin cancer: scope of the problem, management, and role of systemic retinoid chemoprevention. Transplantation Proceedings, 30, 2771–2778.PubMed
134.
Zur Hausen, H. (2000). Papilloma virus causing cancer: evasion from host-cell control in early events in carcinogenesis. Journal of the National Cancer Institute, 92, 690–698.PubMed
135.
De Gruijl, F. R., Van Kranen, H. J., & Mullenders, L. H. F. (2001). UV-induced DNA damage, repair, mutations and oncogenic pathways in skin cancer. Journal of Photochemistry and Photobiology B: Biology, 63, 19–27.
136.
Vogelstein, B., Lane, D., & Levine, A. J. (2000). Surfing the p53 network. Nature, 408, 307–310.PubMed
137.
Randle, H. W. (1996). Basal cell carcinoma. Identification and treatment of the high-risk patients. Dermatological Surgery, 22, 255–261.
138.
Stratton, S. P., Dorr, R. T., & Alberts, D. S. (2000). The state-of-the-art in chemoprevention of skin cancer. European Journal of Cancer, 36, 1292–1297.PubMed
139.
Epstein, E. H. (2008). Basal cell carcinomas: attack of the hedgehog. Nature Reviews Cancer, 8, 743–754.PubMed
140.
Breuninger, H., Schaumburg-Lever, G., Holzschuh, J., & Horny, H. P. (1997). Desmoplastic squamous cell carcinoma of skin and vermilion surface: a highly malignant subtype of skin cancer. Cancer, 79, 915–919.PubMed
141.
Akita, Y., Kozaki, K., Nakagawa, A., Saito, T., Ito, S., Tamada, Y., et al. (2004). Cyclooxygenase-2 is a possible target of treatment approach in conjunction with photodynamic therapy for various disorders in skin and oral cavity. British Journal of Dermatology, 151, 472–480.PubMed
142.
O’Grady, A., O’Kelly, P., Murphy, G. M., Leader, M., & Kay, E. (2004). COX-2 expression correlates with microvessel density in non-melanoma skin cancer from renal transplant recipients and immunocompetent individuals (2004). Human Pathology, 35, 1549–1555.PubMed
143.
Nijsten, T., Colpaert, C. G., Vermeulen, P. B., Harris, A. L., Van Marck, E., & Lambert, J. (2004). Cyclooxygenase-2 expression and angiogenesis in squamous cell carcinoma of the skin and its precursors: a paired immunohistochemical study of 35 cases. British Journal of Dermatology, 151, 837–845.PubMed
144.
Wang, D., & DuBois, R. N. (2004). Cyclooxygenase-2-derived prostaglandin E2 regulates the angiogenic switch. Proceedings of the National Academy of Sciences of the United States of America, 101, 415–416.PubMed
145.
Seo, J. Y., Kim, E. K., Lee, S. H., Park, K. C., Kim, K. H., Eun, H. C., et al. (2003). Enhanced expression of cyclooxygenase-2 by UV in aged human skin in vivo. Mechanisms of Ageing and Development, 124, 903–910.PubMed
146.
Stratton, S. P. (2001). Prevention of non-melanoma skin cancer. Current Oncology Reports, 3, 295–300.PubMed
147.
Lippman, S. M., & Hawk, E. T. (2009). Cancer prevention: from 1727 to milestones of the past 100 years. Cancer Research, 69, 5269–5284.PubMed
148.
Bowden, G. T. (2004). Prevention of non-melanoma skin cancer by targeting ultraviolet-B-light signalling. Nature Review Cancer, 4, 23–35.
149.
Kutchera, W., Jones, D. A., Matsunami, N., Groden, J., MyIntyre, T. M., Zimmermann, G. A., et al. (1996). Prostaglandin H synthase 2 is expressed abnormally in human coloncancer: evidence for a transcriptional effect. Proceedings of the National Academy of Sciences of the United States of America, 93, 4816–4820.PubMed
150.
Kim, Y., & Fischer, S. M. (1998). Transcriptional regulation of cyclooxygenase-2 in mouse skin carcinoma cells. Journal of Biological Chemistry, 273, 27686–27694.PubMed
151.
Ristimäki, A., Garfinkel, S., Wessendorf, J., Maciag, T., & Hla, T. (1994). Induction of cyclo-oxygenase-2 by interleukin-1 alpha. Evidence for posttranscriptional regulation. Journal of Biological Chemistry, 269, 11769–11775.PubMed
152.
Dixon, D. A., Tolley, N. D., King, P. H., Nabors, L. B., McIntyre, T. M., Zimmermann, G. A., et al. (2001). Altered expression of the mRNA stability factor HuR promotes cyclooxygenase-2 expression in colon cancer cells. Journal of Clinical Investigation, 108, 1657–1665.PubMed
153.
Fernau, N. S., Fugmann, D., Leyendecker, M., Reimann, K., Grether-Beck, S., Galban, S., et al. (2010). Role of HuR and p38MAPK in ultraviolet B-induced post-transcriptional regulation of COX-2 expression in the human keratinocyte cell line HaCaT. Journal of Biological Chemistry, 285, 3896–3904.PubMed
154.
Miller, C. C., Hale, P., & Pentland, A. P. (1994). Ultraviolett B injury increases prostaglandin synthesis through a tyrosine kinase-dependent pathway. Journal of Biological Chemistry, 264, 3529–3533.
155.
Ashida, M., Bito, T., Budiyanto, A., Ichihashi, M., & Ueda, M. (2003). Involvement of EGF receptor activation in the induction of cyclooxygenase-2 in HaCaT keratinocytes after UVB. Experimental Dermatology, 12, 445–452.PubMed
156.
Maldve, R. E., Kim, Y., Muga, S. J., & Fischer, S. M. (2000). Prostaglandin E2 regulation of cyclooxygenase expression in keratinocytes is mediated via cyclic nucleotide-linked prostaglandin receptors. Journal of Lipid Research, 41, 873–881.PubMed
157.
Wang, H. Q., & Smart, R. C. (1999). Overexpression of protein kinase C-α in the epidermis of trans-genic mice results in striking alterations in phorbol-ester induced inflammation and COX-2, MIP-2, and TNF-α expression but not tumor promotion. Journal of Cell Science, 112, 3497–3506.PubMed
158.
Wang, H. Q., Kim, M. P., Tiano, H. F., Langenbach, R., & Smart, R. C. (2001). Protein kinase C-α coordinately regulates cytosolic phospholipase A2 activity and expression of cyclooxygenase-2 through different mechanisms in mouse keratinocytes. Molecular Pharmacology, 59, 860–866.PubMed
159.
Chen, W., Tang, Q., Gonzales, M. S., & Bowden, G. T. (2001). Role of p38 MAP kinases and ERK in mediating ultraviolet-B induced cyclooxygenase-2 gene expression in human keratinocytes. Oncogene, 20, 3921–3926.PubMed
160.
Bachelor, M. A., Silvers, A. L., & Bowden, G. T. (2002). The role of p38 in UVA-induced cyclooxygenase-2 expression in the human keratinocyte cell line, HaCaT. Oncogene, 21, 7092–7099.PubMed
161.
Dickinson, S. E., Olson, E. R., Zhang, J., Cooper, S. J., Melton, T., Criswell, P. J., et al. (2011). P38 MAP kinase plays a functional role in UVB-induced mouse skin carcinogenesis. Molecular Carcinogenesis, 50, 469–478.PubMed
162.
Tang, Q., Chen, W., Gonzales, M. S., Finch, J., Inoue, H., & Bowden, G. T. (2001). Role of cyclic AMP responsive element in the UVB induction of cyclooxygenase-2 transcription in human keratinocytes. Oncogene, 20, 5164–5172.PubMed
163.
Tang, Q., Gonzales, M., Inoue, H., & Bowden, G. T. (2001). Roles of Akt and glycogen synthase kinase 3 beta in the ultraviolet B induction of cyclooxygenase-2 transcription in human keratinocytes. Cancer Research, 61, 4329–4332.PubMed
164.
Kosaka, T., Miyata, A., Ihara, H., Hara, S., Sugimoto, T., Takeda, O., et al. (1994). Characterization of the human gene (PTGS2) encoding prostaglandin-endoperoxide synthase 2. European Journal of Biochemistry, 221, 889–897.PubMed
165.
Fletscher, B. S., Kujubu, D. A., Perrin, D. M., & Herschman, H. R. (1992). Structure of the mitogen-inducible TIS 10 gene and demonstration that the TIS-10-encoded protein is a functional prostaglandin G/H synthase. Journal of Biological Chemistry, 267, 4338–4344.
166.
Kraemer, S. A., Meade, E. A., & DeWitt, D. L. (1992). Prostaglandin endoperoxide synthase gene structure: identification of the transcriptional start site and 5’ flanking regulatory sequences. Archives of Biochemistry and Biophysics, 293, 391–400.PubMed
167.
Fritsche, E., Schäfer, C., Calles, C., Bernsmann, T., Bernshausen, T., Wurm, M., et al. (2007). Lightening up the UV response by identification of the arylhydrocarbon receptor as a cytoplasmatic target for ultraviolet B radiation. Proceedings of the National Academy of Sciences of the United States of America, 104, 8851–8856.PubMed
168.
Zhang, J., & Bowden, G. T. (2008). UVB irradiation regulates COX-2 mRNA stability through AMPK and HuR in human keratinocytes. Molecular Carcinogenesis, 47, 974–983.PubMed
169.
Bachelor, M. A., & Bowden, G. T. (2004). UVA-mediated activation of signalling pathways involved in skin tumor promotion and progression. Seminars in Cancer Biology, 14, 131–138.PubMed
170.
Thun, M. J., Henley, S. J., & Patrono, C. (2002). Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. Journal of the National Cancer Institute, 94, 252–266.PubMed
171.
Steinbach, G., Lynch, P. M., Phillips, R. K., Wallace, M. H., Hawk, E., Gordon, G. B., et al. (2000). The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. The New England Journal of Medicine, 342, 1946–1952.PubMed
172.
Rothwell, P. M., Wilson, M., Elwin, C. E., Norrving, B., Algra, A., Warlow, C. P., et al. (2010). Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet, 376, 1741–1750.PubMed
173.
Rothwell, P. M., Fowkes, F. G. R., Belch, J. F. F., Ogawa, H., Warlow, C. P., & Meade, T. W. (2011). Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet, 377, 31–41.PubMed
174.
Coghill, A. E., Newcomb, P. A., Campbell, P. T., Burnett-Hartman, A. N., Adams, S. V., Poole, E. M., et al. (2011). Prediagnostic non-steroidal anti-inflammatory drug use and survival after diagnosis of colorectal cancer. Gut, 60, 491–498.PubMed
175.
Smalley, W. E., & Dubois, R. N. (1997). Colorectal cancer and nonsteroidal anti-inflammatory drugs. Advances in Pharmacology, 39, 1–20.PubMed
176.
Marks, F., & Fürstenberger, G. (2000). Cancer prevention through interruption of multistage carcinogenesis: the lessons learnt by comparing mouse skin carcinogenesis and human large bowel cancer. European Journal of Cancer, 36, 314–329.PubMed
177.
Abel, E. L., Angel, J. M., Kiguchi, K., & DiGiovanni, J. (2009). Multi-stage chemical carcinogenesis in mouse skin: fundamentals and applications. Nature Protocols, 9, 1350–1362.
178.
Marks, F., & Fürstenberger, G. (1995). Tumor promotion in skin. In C. E. Arcos, M. F. Arcos, & Y. T. Woo (Eds.), Chemical induction of cancer (pp. 125–160). Boston: Birkhäuser.
179.
Malanchi, I., Peinado, H., Kassen, D., Hussenet, T., Metzger, D., Chambon, P., et al. (2008). Cutaneous cancer stem cell maintenance is dependent on b-catenin signalling. Nature, 452, 650–653.PubMed
180.
Fraga, M. F., Herranz, M., Espada, J., Ballestar, E., Paz, M. F., Ropero, S., et al. (2004). A mouse skin multi stage carcinogenesis model reflects the aberrant DNA methylation patterns of human tumors. Cancer Research, 64, 5527–5534.PubMed
181.
Müller-Decker, K., Kopp-Schneider, A., Marks, F., Seibert, K., & Fürstenberger, G. (1998). Localization of prostaglandin h synthase isozymes in murine epidermal tumors:suppression of skin tumor promotion by inibition of prostaglandin h synthase 2. Molecular Carcinogenesis, 23, 36–44.PubMed
182.
Müller-Decker, K., Neufang, G., Berger, I., Neumann, M., Marks, F., & Fürstenberger, G. (2002). Transgenic cyclooxygenase-2 overexpression sensitizes mouse skin for carcinogenesis. Proceedings of the National Academy of Sciences of the United States of America, 99, 12483–12488.PubMed
183.
Fürstenberger, G., Gross, M., & Marks, F. (1998). Eicosanoids and multistage carcinogenesis in NMRI mouse skin: role of prostaglandin E and F in conversion (first stage of tumor pro-motion) and promotion (second stage of tumor promotion). Carcinogenesis, 10, 91–96.
184.
Müller, K., Krieg, P., Marks, F., & Fürstenberger, G. (2000). Expression of PGF2α mRNA in normal, hyperplastic and neoplastic skin. Carcinogenesis, 21, 1063–1066.PubMed
185.
Fischer, S. M., Lo, H. H., Gordon, G. B., Seibert, K., Kelloff, G., Lubet, R. A., et al. (1999). Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indo-methacin against ultraviolet-induced skin carcinogenesis. Molecular Carcinogenesis, 25, 231–240.PubMed
186.
Pentland, A. P., Schoggins, J. W., Scott, G. A., Khan, K. N., & Han, R. (1999). Reduction of UV-induced skin tumors in hairless mice by selective COX-2 inhibition. Carcinogenesis, 20, 1939–1944.PubMed
187.
Orengo, I. F., Gerguis, J., Phillips, R., Guevara, A., Lewis, A. T., & Black, H. S. (2002). Celecoxib, a cyclooxygenase 2 inhibitor as potential chemopreventive to UV-induced skin cancer: a study in the hairless mouse model. Archives of Dermatology, 138, 751–755.PubMed
188.
Fischer, S. M., Conti, C. J., Viner, J., Marcelo Aldaz, C., & Lubet, R. A. (2003). Celecoxib and difluoromethylornithine in combination have strong therapeutic activity against UV-induced skin tumors in mice. Carcinogenesis, 24, 945–952.PubMed
189.
Wilgus, T. A., Koki, A. T., Zweifel, B. S., Rubal, P. A., & Oberyszyn, T. M. (2003). Chemotherapeutic efficacy of topical celecoxib in a murine model of ultraviolet light B-induced skin cancer. Molecular Carcinogenesis, 38, 33–39.PubMed
190.
Wilgus, T. A., Breza, T. S., Tober, K. L., & Oberyszyn, T. M. (2004). Treatment with 5-fluorouracil and celecoxib displays synergistic regression of ultraviolet light B-induced skin tumors. Journal of Investigative Dermatology, 122, 1488–1494.PubMed
191.
Soontrapa, K., Honda, T., Sakata, D., Yao, C., Hirata, T., Hori, S., et al. (2011). Prostaglandin E2-prostaglandin E receptor subtype 4 (EP4) signaling mediates UV irradiation-induced systemic immunosuppression. Proceedings of the National Academy of Sciences of the United States of America, 108, 6668–6673.PubMed
192.
Elmets, C. A., Viner, J. L., Pentland, A. P., Cantrell, W., Lin, H. Y., Bailey, H., et al. (2010). Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial. Journal of the National Cancer Institute, 102, 1835–1844.PubMed
193.
Oshima, M., Dinchuk, J. E., Kargman, S. L., Oshima, H., Hancock, B., Kwong, E., et al. (1996). Suppression of intestinal polyposis in APC716 knockout mice by inhibition of cyclooxygenase-2 (COX-2). Cell, 87, 803–809.PubMed
194.
Chulada, P. C., Thompson, M. B., Mahler, J. F., Doyle, C. M., Gaul, B. W., Lee, C., et al. (2000). Genetic disruption of Ptgs-1, as well as of Ptgs-2, reduces intestinal tumorigenesis in min mice. Cancer Research, 60, 4705–4708.PubMed
195.
Wiese, F. W., Thompson, P. A., & Kadlubar, F. F. (2001). Carcinogen substrate specificity of human COX-1 and COX-2. Carcinogenesis, 21, 5–10.
196.
Fuchs, E. (1995). Keratins and the skin. Annual Reviews of Cellular and Devlopmental Biology, 11, 123–153.
197.
Pentland, A. P., Scott, G., VanBuskirk, J. A., Tanck, C., LaRossa, G., & Brouxhon, S. (2004). Cyclooxygenase-1 deletion enhances apoptosis but does not protect against ultraviolet light-induced tumors. Cancer Research, 64, 5587–5591.PubMed
198.
Rundhaug, J. E., Pavone, A., Kim, E., & Fischer, S. M. (2007). The effect of cyclooxygenase-2 overexpression on skin carcinogenesis is context dependent. Molecular Carcinogenesis, 46, 981–992.PubMed
199.
Bol, D. K., Rowley, R. B., Ho, C. P., Pilz, B., Dell, J., Swerdel, M., et al. (2002). Cyclooxygenase-2 overexpression in the skin of transgenic mice results in suppression of tumor development. Cancer Research, 62, 2516–2521.PubMed
200.
Tjiu, J. W., Liao, Y. H., Lin, S. J., Huang, Y. L., Tsai, W. L., Chu, C., et al. (2006). Cyclooxygenase-2 overexpression in human basal cell carcinoma cell line increases antiapoptosis, angiogenesis, and tumorigenesis. Journal of Investigative Dermatology, 126, 1143–1151.PubMed
201.
Tjiu, J. W., Chen, J. S., Shun, C. T., Lin, S. J., Liao, Y. H., Chu, C. Y., et al. (2009). Tumor-associated macrophage-induced invasion and angiogenesis of human basal cell carcinoma cells by cyclooxygenase-2 induction. Journal of Investigative Dermatology, 129, 1016–1025.PubMed
202.
Tang, J. Y., Aszterbaum, M., Athar, M., Barsanti, F., Cappola, C., Estevez, N., et al. (2010). Basal cell carcinoma chemoprevention with nonsteroidal anti-inflammatory drugs in genetically predisposed PTCH1+/− humans and mice. Cancer Prevention Research, 3, 25–34.PubMed
203.
Grau, M. V., Baron, J. A., Langholz, B., Karagas, M., Greenberg, E. R., Stukel, T. A., et al. (2006). Effect of NSAIDs on the recurrence of non-melanoma skin cancer. International Journal of Cancer, 119, 682–686.
204.
Vogel, U., Christensen, J., Wallin, H., Friis, S., Nexo, B. A., & Tjonneland, A. (2007). Polymorphisms in COX-2, NSAID use and risk of basal cell carcinoma in a prospective study of Danes. Mutation Research, 617, 138–146.PubMed
205.
Clouser, M. C., Roe, D. J., Foote, J. A., & Harris, R. B. (2009). Effect of non-steroidal anti-inflammatory drugs on non-melanoma skin cancer incidence in the SKICAP AK trial. Pharmacoepidemiology and Drug Safety, 18, 276–283.PubMed
206.
Butler, G. J., Neale, R., Green, A. C., Pandeya, N., & Whiteman, D. C. (2005). Nonsteroidal anti-inflammatory drugs and the risk of actinic keratoses and squamous cell cancers of the skin. Journal of the American Academy of Dermatology, 53, 966–972.PubMed
207.
Curiel-Lewandrowski, C., Nijsten, T., Gomez, M. L., Hollestein, L. M., Atkins, M. B., & Stern, R. S. (2011). Long-term use of non-steroidal anti-inflammatory drugs decreases the risk of cutaneous melanoma: results of a united states case–control study. Journal of Investigative Dermatology, 131, 1460–1468.PubMed
208.
Asgari, M., White, E., & Chren, M. M. (2004). Nonsteroidal anti-inflammatory drug use in the prevention and treatment of squamous cell carcinoma. Dermatological Surgery, 30, 1335–1342.
209.
Van Der Geer, S., & Krekels, G. A. M. (2009). Treatment of actinic keratoses on the dorsum of the hands: ALA-PDT versus diclofenac 3% gel followed by ALA-PDT. A placebo-controlled, double-blind, pilot study. Journal of Dermatology and Treatment, 20, 259–265.
210.
Fecker, L. F., Stockfleth, E., Braun, F. K., Rodust, P. M., Schwarz, C., Köhler, A., et al. (2010). Enhanced death ligand-induced apoptosis in cutaneous SCC cells by treatment with diclofenac/Hyaluronic acid correlates with downregulation of c-FLIP. Journal of Investigative Dermatology, 130, 2098–2109.PubMed
211.
Solomon, S. D., McMurray, J. J. V., Pfeffer, M. A., Wittes, J., Fowler, R., Finn, P., et al. (2005). Cardiovascular adverse effects associated with celecoxib in a clinical trial for colorectal adenoma prevention. The New England Journal of Medicine, 352, 1071–1080.PubMed
212.
Solomon, S. D., Wittes, J., Finn, P. V., Fowler, R., Viner, J., Bertagnolli, M. M., et al. (2008). Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: The cross trial safety analysis. Circulation, 117, 2104–2113.PubMed
Metadata
Title
Cyclooxygenase-dependent signaling is causally linked to non-melanoma skin carcinogenesis: pharmacological, genetic, and clinical evidence
Author
Karin Müller-Decker
Publication date
01-12-2011
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 3-4/2011
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-011-9306-z

Other articles of this Issue 3-4/2011

Cancer and Metastasis Reviews 3-4/2011 Go to the issue

OriginalPaper

COX inhibitors directly alter gene expression: role in cancer prevention?

OriginalPaper

The thromboxane synthase and receptor signaling pathway in cancer: an emerging paradigm in cancer progression and metastasis

OriginalPaper

Cyclooxygenase- and lipoxygenase-mediated DNA damage

OriginalPaper

Dissecting the role of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) in colon, breast, and lung carcinogenesis

OriginalPaper

15-Lipoxygenase-1 as a tumor suppressor gene in colon cancer: is the verdict in?

OriginalPaper

Prostaglandin E2 EP receptors as therapeutic targets in breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits